Investigating Alzheimer's biomarkers in tears and blood
Official title: Examination of Alzheimer's Disease Biomarkers in Tears and Dry Blood Spots
Run by Danish Dementia Research Centre · NCT06567431 · Data updated 2026-11-12
This study is testing if we can find signs of Alzheimer's disease in tears and blood samples from people already diagnosed with Alzheimer's and other types of dementia.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 30 Years and up |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | Danish Dementia Research Centre Research network |
| Locations | 1 site (Copenhagen) |
| Status | Recruiting |
| Started | March 18, 2024 |
| Main results expected | January 31, 2026 |
| Study ends | December 31, 2028 |
| Registry record updated | August 22, 2024 |
| Trial ID | NCT06567431 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals diagnosed with Alzheimer's disease, Dementia with Lewy Bodies, Frontotemporal dementia, vascular dementia, or Normal pressure hydrocephalus who are undergoing a lumbar puncture.
✕Probably not a fit
Patients who do not require a lumbar puncture or those deemed clinically unfit for participation will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the presence of Alzheimer's disease biomarkers in tear fluid and dried blood spots from patients diagnosed with Alzheimer's and other forms of dementia. Participants scheduled for a lumbar puncture at the Memory Clinic will provide tear fluid and blood samples on the same day. Additionally, a sub-study will involve participants repeating the dried blood spot collection at home one week later. The collected samples will be analyzed for Alzheimer's-related pathology alongside cerebrospinal fluid.
Why it matters
Potential benefit: If successful, this study could lead to non-invasive methods for diagnosing and monitoring Alzheimer's disease.
How similar studies have gone: While the approach of using tear fluid for biomarker analysis is innovative, similar studies have shown promise in other contexts, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Inclusion criteria for patients: * Lumbar puncture with CSF avaiable for analysis * Diagnosis of Alzheimer's disease, Dementia with Lewy Bodies (DLB), Frontotemporal dementia (FTD), vascular dementia (VaD) or Normal pressure hydrocephalus (NPH) * Of legal age. Inclusion criteria for controls: * Lumbar puncture with CSF avaiable for analysis * No neurological disease. * Of legal age. Exclusion Criteria: * No lumbar puncture * Clinically assessed as unfit to participate in the project.
Where it's running
-
Danish Dementia Research Centre
Copenhagen, Denmark Recruiting
Study contacts
- Study coordinator: Steen G Hasselbalch, DMSc
- Email: steen.gregers.hasselbalch@regionh.dk
- Phone: +4535456922
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Registering medical data and care outcomes for ALS, SMA, and other motor disorders
This registry slowly collects routine-care information from adults with ALS, SMA, or other motor disorders to see how they’re treated and how care affects outcomes.
-
Prenatal education to reduce environmental exposures during pregnancy
Aimed at pregnant people, this program tests whether a classroom-style education can help reduce exposure to harmful pollutants from seafood and nearby pollution sources.
-
Hyperspectral retinal imaging to detect Alzheimer’s and other neurodegenerative changes
This project will test whether a special retinal camera that scans many wavelengths of light can detect signs of Alzheimer’s and other neurodegenerative diseases in people with dementia or at risk.
-
Increasing daily physical activity to slow cognitive decline in alpha-synuclein disorders
This study will test whether using a motivational smartphone app to increase everyday physical activity can help slow cognitive decline in people aged 50–80 with isolated REM sleep behavior disorder (an early sign of alpha‑synuclein disease).
-
VIRADIA: a virtual reality app for neurological and cognitive testing
This project tests whether the VIRADIA virtual reality app gives comparable results to standard paper or in-person neurological and cognitive tests for adults with and without neurological conditions.
-
Following memory decline in Alzheimer disease
This project will use 7T MRI, EEG, blood and stool samples, and memory tests to see if they can track memory decline in people over 55 with Alzheimer's disease or mild cognitive impairment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.